Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 3763 3783
This examiner grants 66% of resolved cases
Leah Jennings Swanson serves in Tech Center 3700 and Art Unit 3763. With 434 resolved cases, the examiner has an allowance rate of 65.7 percent. This 65.7 percent rate indicates a generally favorable environment for applicants, with most cases ending in an allowance. The 434 resolved cases provide a robust data set, making these metrics a reliable indicator of the examiner's typical prosecution style.
The data shows an interview lift of 38.6 percent. This 38.6 percent lift suggests that interviews are effective at moving cases toward a grant with this examiner. The median days to allowance is 1220. Given the 434 resolved cases, practitioners should consider an interview as a primary tactic. The 38.6 percent lift is a tool for overcoming rejections and ensuring that applications reach an allowance within the 1220-day median timeframe. This strategy can significantly improve the probability of success compared to the base allowance rate.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17361762 | CLOSED LOOP CONTROL SYSTEM WITH SAFETY PARAMETERS AND METHODS | Final Rejection | Abbott Diabetes Care Inc. |
| 18700816 | Systems and Methods for Angled Insertion of Microneedles for Targeted Delivery | Non-Final OA | Georgia Tech Research Corporation |
| 18251522 | DEVICE ASSEMBLY FOR NEEDLELESS SYRINGE | Final Rejection | DAICEL CORPORATION |
| 18140234 | ANTI-VACUUM SURGE (AVS) WITH IMPROVED FOLLOWABILITY | Non-Final OA | JOHNSON & JOHNSON SURGICAL VISION, INC. |
| 17446147 | System, Apparatus and Method for Maintaining Anterior Chamber Intraoperative Intraocular Pressure | Final Rejection | Johnson & Johnson Surgical Vision, Inc. |
| 18912132 | FILTER FOR IV SET | Non-Final OA | CareFusion 303, Inc. |
| 18514022 | FLUID LINE OCCLUSION DETECTION SYSTEM AND METHODS | Final Rejection | CareFusion 303, Inc. |
| 17208994 | CATHETER ADAPTER PUSH TAB AND RELATED DEVICES, SYSTEMS, AND METHODS | Non-Final OA | Becton, Dickinson and Company |
| 16889398 | CATHETER ASSEMBLY FLUSHING DEVICE AND RELATED METHODS | Non-Final OA | Becton, Dickinson and Company |
| 18597028 | Integrating Electronics into the Stopper of a Cartridge | Final Rejection | Sanofi |
| 18145564 | Auto-Injector | Final Rejection | Sanofi-Aventis Deutschland GMBH |
| 18571423 | ADVANCED EAR ACCESS | Non-Final OA | COCHLEAR LIMITED |
| 18292133 | SPARK GENERATOR FOR GENERATING PRESSURE, FORMULA INJECTOR COMPRISING SPARK GENERATOR, METHOD FOR GENERATING PRESSURE BY SPARK, AND METHOD FOR INJECTING FORMULA | Non-Final OA | L'Oreal |
| 17888048 | CATHETER ASSEMBLY | Final Rejection | TERUMO KABUSHIKI KAISHA |
| 18386647 | PROGRAMMATIC MEDICAMENT TITRATION WITH A MEDICAMENT DELIVERY DEVICE | Final Rejection | INSULET CORPORATION |
| 16995527 | RATCHET DRIVE FOR ON BODY DELIVERY SYSTEM | Final Rejection | Insulet Corporation |
| 16859544 | FILLING ASSIST MECHANISMS AND KEYED INTERFACES FOR DRUG DELIVERY DEVICES | Final Rejection | INSULET CORPORATION |
| 17509196 | Microneedle Systems and Apparatus | Final Rejection | DEKA Products Limited Partnership |
| 18023230 | DRUG CARTRIDGE, CASSETTE, DRUG INJECTION DEVICE, AND DRUG INJECTION SYSTEM | Non-Final OA | PHC Holdings Corporation |
| 17293968 | ACTUATING COMPONENTS AND RELATED METHODS | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 18616119 | Syringe-Based Microbubble Generator | Final Rejection | Agitated Solutions Inc. |
| 18398051 | CAP FOR USE WITH VARIETY OF INJECTION PENS AND RELATED DEVICES AND METHODS | Non-Final OA | Bigfoot Biomedical, Inc. |
| 18222978 | SOFT TIP CANNULA WITH RETRACTABLE TIP PROTECTOR | Non-Final OA | ALTAVIZ, LLC |
| 18650596 | DEVICES AND METHODS FOR DELIVERING A LYOPHILIZED MEDICAMENT | Non-Final OA | kaleo, Inc. |
| 17625260 | DRUG ACCOMMODATING DEVICE OF SOLID ORAL FORMULATION, AND ORAL ADMINISTRATION AND DELIVERY APPARATUS COMPRISING SAME | Final Rejection | SHANGHAI WD PHARMACEUTICAL CO., LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy